Browsing Category
Pharma Industry News
4028 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
How China’s lymphoma treatment landscape could evolve with HMPL-760’s registrational study
Can HMPL-760 reshape lymphoma treatment? Explore HUTCHMED’s Phase III strategy and what it means for BTK competition.
Can a new IL-13 drug quietly challenge Dupixent’s dominance in eczema treatment?
Apogee Therapeutics’ APEX data could reshape eczema treatment competition. Discover what it means for Dupixent, Ebglyss, and investors.
Clover Biopharmaceuticals stock in focus as new RSV re-vaccination data targets a gap GSK has not solved
Clover Biopharmaceuticals says new RSV re-vaccination data beat Arexvy in older adults. Read what this could mean for the adult vaccine market.
How the OptimUM-02 trial timeline may influence investor and clinical sentiment in ocular oncology
IDEAYA Biosciences nears darovasertib data. Find out how this Phase 3 readout could reshape metastatic uveal melanoma treatment today.
Radiopharm Theranostics RAD 101 hits primary endpoint in 90% of brain metastasis patients at second Phase 2b interim analysis
Radiopharm Theranostics RAD 101 achieves 90% PET-MRI concordance in brain metastases Phase 2b trial. Full data due June 2026. Read more.
Gilead Sciences bets $2.2bn on immune reset with Ouro Medicines BCMAxCD3 bispecific acquisition
Gilead Sciences agrees to acquire Ouro Medicines for up to $2.175bn, adding BCMA T cell engager gamgertamig to its inflammation pipeline. Read the full strategic analysis.
GlycoNex and Nippon Kayaku team up to advance next-generation ADC candidate GNX201-ADC in solid tumours
GlycoNex (4168) and Nippon Kayaku advance GNX201-ADC, a protease-activated ADC targeting solid tumours. Discover what this deal means for oncology. Read more.
Can Insilico Medicine’s PandaClaw agentic AI platform accelerate pharma software licensing revenue growth in 2026?
Insilico Medicine launches PandaClaw, an agentic AI tool that lets biologists run autonomous multi-omics drug discovery analysis. Read what it means for pharma.
Why Dai Nippon Printing chose Hyderabad for its second overseas R&D hub as 7912 retreats from 52-week highs
Dai Nippon Printing (TSE: 7912) opens an IIT Hyderabad R&D base for EV wireless charging and pharma APIs. Read the full strategic analysis.
Amplia Therapeutics (ASX:ATX) reports five complete responses and improved survival in ACCENT pancreatic cancer trial
Amplia Therapeutics (ASX:ATX) posts 7.8% complete response rate and 11.1-month mOS in ACCENT pancreatic cancer trial. Read the full strategic analysis.